Atossa Therapeutics (NASDAQ:ATOS) Stock Rating Lowered by StockNews.com

StockNews.com downgraded shares of Atossa Therapeutics (NASDAQ:ATOS) from a hold rating to a sell rating in a research report report published on Friday morning.

ATOS has been the subject of several other reports. Ascendiant Capital Markets upped their target price on Atossa Therapeutics from $6.25 to $6.50 and gave the stock a “buy” rating in a research note on Wednesday, September 11th. HC Wainwright reaffirmed a “buy” rating and set a $6.00 target price on shares of Atossa Therapeutics in a research note on Thursday, October 31st.

Atossa Therapeutics Stock Up 8.0 %

Atossa Therapeutics stock opened at $1.62 on Friday. Atossa Therapeutics has a 52 week low of $0.62 and a 52 week high of $2.31. The stock has a 50-day moving average price of $1.44 and a 200 day moving average price of $1.38.

Atossa Therapeutics (NASDAQ:ATOS) last announced its earnings results on Monday, August 12th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.01. Research analysts anticipate that Atossa Therapeutics will post -0.22 EPS for the current year.

Institutional Trading of Atossa Therapeutics

Large investors have recently made changes to their positions in the company. XTX Topco Ltd purchased a new stake in shares of Atossa Therapeutics during the second quarter worth approximately $29,000. Intech Investment Management LLC purchased a new stake in Atossa Therapeutics in the 3rd quarter valued at $29,000. SG Americas Securities LLC grew its holdings in Atossa Therapeutics by 254.3% in the 3rd quarter. SG Americas Securities LLC now owns 41,849 shares of the company’s stock valued at $64,000 after buying an additional 30,037 shares in the last quarter. Cetera Advisors LLC purchased a new stake in Atossa Therapeutics in the 1st quarter valued at $72,000. Finally, Virtu Financial LLC purchased a new stake in Atossa Therapeutics in the 1st quarter valued at $151,000. 12.74% of the stock is currently owned by hedge funds and other institutional investors.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.